Lurasidone Tablets Suppliers & Bulk Manufacturers
Available Forms: Oral Tablets
Available Strengths: 20 mg, 40 mg, 60 mg, 80 mg, 120 mg
Reference Brands: Latuda® (US)
Category:
Antipsychotropic Drugs
Lurasidone is an atypical antipsychotic that works by antagonizing dopamine D2 and serotonin 5-HT2A receptors, helping to reduce psychotic and mood disorder symptoms. It also has partial agonist activity at 5-HT1A receptors, contributing to mood stabilization. Lurasidone tablets are used to treat schizophrenia and bipolar depression (bipolar I disorder) in adults and adolescents. The medication offers a favorable metabolic profile, making it suitable for long-term use in managing psychiatric conditions.
Lurasidone Tablets is available in Oral Tablets
and strengths such as 20 mg, 40 mg, 60 mg, 80 mg, 120 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lurasidone Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lurasidone Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lurasidone tablets are FDA-approved in the United States for the treatment of schizophrenia and bipolar depression (bipolar I disorder) in adults and adolescents. In the European Union, Lurasidone is authorized under the brand name Latuda for schizophrenia in adults and adolescents aged 13 years and older, via centralized EMA procedures.
Regulatory requirements include GMP-compliant manufacturing, clinical trial data demonstrating efficacy and safety, and documentation addressing metabolic effects, akathisia, and suicidality risks. U.S. submissions must comply with boxed warning requirements, while EMA approval requires Risk Management Plans (RMPs) and ongoing pharmacovigilance.
To explore dossier-ready Lurasidone tablets and sourcing options, visit Pharmatradz.com — your trusted B2B pharma partner.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing